You are here
Researchers from King Saud University’s Walid Kayyali Chair for Pharmaceutical Industry recently received a European patent for a new type of aspirin medication that reduces the risk of inflamed stomach tissue that is often associated with taking aspirin.
The new medication reduces the side effects normally associated with aspirin, such as stomach inflammation and peptic ulcers, by combining the main ingredient of aspirin - acetylsalicylic acid – with glutamic acid, an amino acid present in meat, poultry, dairy products, and many other foods.
Dr Alanazi said that test results from animal trials of the medication revealed no change in stomach linings, and no difference between the tissue of animals given the medication and those who given no medication.
Al-Saleh also said a patent application for the medication is currently under review with the US Patent and Trademark Office.
The invention had earlier received a patent from the Saudi patent office.
- KSU receives patent for revolutionary new water filtration material
- KSU team earns U.S., European patents for anesthetic after decade-long research